LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-ß1/Smad3/NF-&#954;B pathway.

LOXL2 silencing suppresses angiotensin II-induced cardiac hypertrophy through the EMT process and TGF-ß1/Smad3/NF-κB pathway.

Luo, Jun; Wu, Yingbiao; Zhu, Xi; Wang, Saihua; Zhang, Xiaogang; Ning, Zhongping.

Afiliação

Luo J; Department of Cardiology, Shanghai University of Medicine & Health Sciences affiliated Zhoupu Hospital, Shanghai 201318, China.
Wu Y; These authors contributed eqully to this work.
Zhu X; Department of Cardiology, Shanghai University of Medicine & Health Sciences affiliated Zhoupu Hospital, Shanghai 201318, China.
Wang S; These authors contributed eqully to this work.
Zhang X; Department of Cardiology, Shanghai University of Medicine & Health Sciences affiliated Zhoupu Hospital, Shanghai 201318, China.
Ning Z; Department of Cardiology, Shanghai University of Medicine & Health Sciences affiliated Zhoupu Hospital, Shanghai 201318, China.

Iran J Basic Med Sci ; 25(8): 964-969, 2022 Aug.

Article em En | MEDLINE | ID: mdl-36159334